Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2017 CR = complete remission; CRc = composite complete remission; ORR = overall response; OS = overall survival; mLDAC = modified low-dose cytarabine; DAC = decitabine; ECOG PS = the Eastern Cooperative Oncology Group performance statu; HCT-CI = the hematopoietic cell transplant co-morbidity index; MRC = myelodysplasia-related change; PB = peripheral blood; BM = bone marrow; LDH = lactate dehydrogenase; UNL = upper normal limit. 3 UPN = unique patient number; OS = overall survival; mLDAC = modified low-dose cytarabine; NR = no response; NA = not available; DAC = decitabine; CR = complete remission; PR = partial remission; CRi = incomplete complete remission * calculated from date of mLDAC administration as a salvage treatment to any cause of death or last follow-up. -behenoyl-1-β-D-arabinofuranosyl cytosine; NR = no response; NA = not available; CR = complete remission; CRp = complete remission without platelet recovery; CRi = incomplete complete remission; DAC = decitabine. * calculated from date of abbreviated ICTx. administration as a salvage treatment to any cause of death or last follow-up. 
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